Autolus Therapeutics (NASDAQ:AUTL – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a report issued on Monday,Benzinga reports. They currently have a $10.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 344.44% from the company’s current price.
A number of other analysts have also recently weighed in on the stock. The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $10.40.
Get Our Latest Report on Autolus Therapeutics
Autolus Therapeutics Stock Performance
Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter in the prior year, the firm posted ($0.26) EPS. As a group, equities analysts expect that Autolus Therapeutics will post -0.94 earnings per share for the current year.
Institutional Investors Weigh In On Autolus Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of AUTL. Wellington Management Group LLP lifted its position in shares of Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock worth $87,919,000 after buying an additional 6,330,392 shares during the last quarter. FMR LLC raised its position in shares of Autolus Therapeutics by 44.6% in the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after purchasing an additional 5,478,706 shares during the period. Great Point Partners LLC lifted its stake in shares of Autolus Therapeutics by 195.0% in the second quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock worth $11,977,000 after buying an additional 2,275,000 shares during the last quarter. Armistice Capital LLC lifted its position in Autolus Therapeutics by 33.8% during the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock worth $21,750,000 after acquiring an additional 1,578,000 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its holdings in Autolus Therapeutics by 27.4% during the second quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock valued at $14,964,000 after acquiring an additional 925,000 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Read More
- Five stocks we like better than Autolus Therapeutics
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Delta Can Fly to New Highs in 2025; Here’s Why
- What to Know About Investing in Penny Stocks
- Snowflake Stock: Bullish Upgrades Demand Investors’ Attention
- ESG Stocks, What Investors Should Know
- 3 Dividend Stocks With Growth Potential You Can’t Miss
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.